#Olive leaf extract code

#Olive leaf extract code

This study was registered at PROSPERO with the code CRD42022302395.Ĭardiovascular disease (CVD) is one of the most prominent noncommunicable diseases (NCDs), accounting for the most NCD deaths in the world. As the quality of evidence for glucose hemostasis variables, liver, kidney, and inflammatory markers, were low-to-very low, higher quality RCTs may impact the overarching results. The present study revealed that supplementation with OLE yielded beneficial effects for blood pressure and lipid profile in adults, especially in patients with hypertension. However, no meaningful changes were seen in glucose hemostasis, liver and kidney, or inflammatory markers. Significant reductions were also observed in TC (− 6.69 mg/dl), TG (− 9.21 mg/dl), and SBP (− 7.05 mmHg) in normal-weight individuals. Subgroup analyses also revealed a significant improvement in SBP (− 4.81 mmHg) and diastolic blood pressure (− 2.45 mmHg), TG (− 14.42 mg/dl), total cholesterol (TC) (− 9.14 mg/dl), and low-density lipoprotein-C (LDL-C) (− 4.6 mg/dl) measurements, in patients with hypertension. Twelve studies (n = 819 participants) were included in our analyses. The methodological quality, as well as quality of evidence were assessed using standard tools. Mean differences and standard deviations were pooled for all outcomes, using a random-effects model. PubMed, ISI Web of Science, Scopus, and Cochrane library were searched, up to October 2021, for relevant controlled trials. The aim of this systematic review and meta-analysis was to determine the effect of olive leaf extract (OLE) supplementation on cardiovascular-related variables, including lipid, glycemic, inflammatory, liver and renal-related factors, as well as blood pressure.